Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACP-105 是选择性的、可口服的雄激素受体调节剂 , 能够作用于野生型 AR (pEC50:9.0)和 T877A 突变型 AR (pEC50:9.3)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 453 | 现货 | ||
2 mg | ¥ 632 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,390 | 现货 | ||
25 mg | ¥ 2,820 | 现货 | ||
50 mg | ¥ 3,970 | 现货 | ||
100 mg | ¥ 5,730 | 现货 | ||
500 mg | ¥ 11,500 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 983 | 现货 |
产品描述 | ACP-105 is a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. |
靶点活性 | AR (T877A):9.3 (pEC50), AR (WT):9.0 (pEC50) |
体外活性 | ACP-105 is an orally available, selective amd potent androgen receptor modulator (SARM), with pEC50s of 9.0 and 9.3 for AR wild type and T877A mutant, respectively. The half-lives of ACP-105 (compound 1) in human hepatocytes is measured and found to be 5.0 h[1]. |
体内活性 | Irradiation impaired sensorimotor function in vehicle-treated mice but not in ACP-105-treated mice. Irradiation impaired cued fear conditioning and ACP-105 enhanced fear conditioning in sham-irradiated and irradiated mice. There are relatively early radiation-induced behavioral changes in female mice and reduced MAP-2 levels in the sensorimotor cortex following ACP-105 treatment might contribute to enhanced rotorod performance[2]. |
分子量 | 290.79 |
分子式 | C16H19ClN2O |
CAS No. | 899821-23-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (206.33 mM)
Ethanol: 60 mg/mL(206.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.4389 mL | 17.1945 mL | 34.3891 mL | 85.9727 mL |
5 mM | 0.6878 mL | 3.4389 mL | 6.8778 mL | 17.1945 mL | |
10 mM | 0.3439 mL | 1.7195 mL | 3.4389 mL | 8.5973 mL | |
20 mM | 0.1719 mL | 0.8597 mL | 1.7195 mL | 4.2986 mL | |
50 mM | 0.0688 mL | 0.3439 mL | 0.6878 mL | 1.7195 mL | |
100 mM | 0.0344 mL | 0.1719 mL | 0.3439 mL | 0.8597 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ACP-105 899821-23-9 Endocrinology/Hormones Androgen Receptor ACP 105 inhibit ACP105 Inhibitor inhibitor